SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Stake in Ekso Bionics Holdings

Investment firm Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9.99% in Ekso Bionics Holdings, Inc., holding 2,996,732 shares of common stock.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in EKSO BIONICS HOLDINGS, INC.
• As of March 31, 2025, the Reporting Persons beneficially own an aggregate of 2,996,732 shares of EKSO BIONICS HOLDINGS, INC. Common Stock.
• This ownership represents 9.99% of the issuer's outstanding common stock.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• Both Armistice Capital, LLC and Steven Boyd share voting and dispositive power over all 2,996,732 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of a significant beneficial ownership stake. The maintenance of a nearly 10% stake by a notable investment firm can be viewed as a moderately positive signal of confidence in the company, although the filing itself is purely factual and does not express explicit sentiment.

Positives

• A significant institutional investor, Armistice Capital, LLC, and its managing member, Steven Boyd, maintain a substantial 9.99% stake in Ekso Bionics Holdings, Inc., indicating continued interest.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of significant beneficial ownership by an investment firm in a publicly traded company. It does not provide specific industry context or trends for the robotics or medical device sectors in which Ekso Bionics operates, beyond indicating continued investment interest from a notable fund.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional ownership stake, which can influence market perception and potentially provide stability or a signal of confidence.

Key Dates

Keywords

Ekso Bionics Holdings Inc., Armistice Capital LLC, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Management